215 related articles for article (PubMed ID: 29468444)
1. The expression of the MSC-marker CD73 and of NF2/Merlin are correlated in meningiomas.
Kirches E; Steffen T; Waldt N; Hebert E; Pachow D; Wilisch-Neumann A; Keilhoff G; Schneider T; Braunsdorf WEK; Warnke JP; Mawrin C
J Neurooncol; 2018 Jun; 138(2):251-259. PubMed ID: 29468444
[TBL] [Abstract][Full Text] [Related]
2. Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness.
Tanahashi K; Natsume A; Ohka F; Motomura K; Alim A; Tanaka I; Senga T; Harada I; Fukuyama R; Sumiyoshi N; Sekido Y; Wakabayashi T
J Neuropathol Exp Neurol; 2015 Jul; 74(7):704-9. PubMed ID: 26049897
[TBL] [Abstract][Full Text] [Related]
3. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
4. Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
Waldt N; Scharnetzki D; Kesseler C; Kirches E; Stroscher N; Böhmer FD; Mawrin C
J Neurol Sci; 2020 Jan; 408():116553. PubMed ID: 31715329
[TBL] [Abstract][Full Text] [Related]
5. The significance of immunohistochemical expression of merlin, Ki-67, and p53 in meningiomas.
Pavelin S; Bečić K; Forempoher G; Tomić S; Capkun V; Drmić-Hofman I; Mrklić I; Lušić I; Pogorelić Z
Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):46-9. PubMed ID: 23455188
[TBL] [Abstract][Full Text] [Related]
6. Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence.
Ongaratti BR; Silva CB; Trott G; Haag T; Leães CG; Ferreira NP; Oliveira MC; Pereira-Lima JF
Braz J Med Biol Res; 2016; 49(4):e5125. PubMed ID: 27007654
[TBL] [Abstract][Full Text] [Related]
7. Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas.
Wallesch M; Pachow D; Blücher C; Firsching R; Warnke JP; Braunsdorf WEK; Kirches E; Mawrin C
J Neurol Sci; 2017 Sep; 380():112-121. PubMed ID: 28870549
[TBL] [Abstract][Full Text] [Related]
8. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.
James MF; Lelke JM; Maccollin M; Plotkin SR; Stemmer-Rachamimov AO; Ramesh V; Gusella JF
Neurobiol Dis; 2008 Feb; 29(2):278-92. PubMed ID: 17962031
[TBL] [Abstract][Full Text] [Related]
9. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
[TBL] [Abstract][Full Text] [Related]
10. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
[TBL] [Abstract][Full Text] [Related]
11. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
[TBL] [Abstract][Full Text] [Related]
12. Merlin expression in secretory meningiomas: evidence of an NF2-independent pathogenesis? Immunohistochemical study.
Buccoliero AM; Gheri CF; Castiglione F; Ammannati F; Gallina P; Taddei A; Garbini F; Rossi Degl'Innocenti D; Arganini L; Di Lorenzo N; Mennonna P; Taddei GL
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):353-7. PubMed ID: 17721284
[TBL] [Abstract][Full Text] [Related]
13. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas.
Gutmann DH; Giordano MJ; Fishback AS; Guha A
Neurology; 1997 Jul; 49(1):267-70. PubMed ID: 9222206
[TBL] [Abstract][Full Text] [Related]
14. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of NF2 gene deletion in pediatric meningiomas using chromogenic in situ hybridization.
Begnami MD; Rushing EJ; Santi M; Quezado M
Int J Surg Pathol; 2007 Apr; 15(2):110-5. PubMed ID: 17478763
[TBL] [Abstract][Full Text] [Related]
16. In situ detection of CD73+ CD90+ CD105+ lineage: Mesenchymal stromal cells in human placenta and bone marrow specimens by chipcytometry.
Consentius C; Mirenska A; Jurisch A; Reinke S; Scharm M; Zenclussen AC; Hennig C; Volk HD
Cytometry A; 2018 Jul; 93(9):889-893. PubMed ID: 30211969
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal Stem Cell Marker Expression in Gastric Cancer Stroma.
Numakura S; Uozaki H; Kikuchi Y; Watabe S; Togashi A; Watanabe M
Anticancer Res; 2019 Jan; 39(1):387-393. PubMed ID: 30591485
[TBL] [Abstract][Full Text] [Related]
18. Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma.
Maze EA; Agit B; Reeves S; Hilton DA; Parkinson DB; Laraba L; Ercolano E; Kurian KM; Hanemann CO; Belshaw RD; Ammoun S
Cancer Res; 2022 Jan; 82(2):235-247. PubMed ID: 34853069
[TBL] [Abstract][Full Text] [Related]
19. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases.
Maxwell M; Shih SD; Galanopoulos T; Hedley-Whyte ET; Cosgrove GR
J Neurosurg; 1998 Mar; 88(3):562-9. PubMed ID: 9488313
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of beta-catenin/E-cadherin in meningiomas.
Brunner EC; Romeike BF; Jung M; Comtesse N; Meese E
Histopathology; 2006 Aug; 49(2):178-87. PubMed ID: 16879395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
